HE4 Lentiviral Activation Particles (m): sc-426693-LAC
- Target species: mouse
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- HE4 Lentiviral Activation Particles (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- HE4 Lentiviral Activation Particles (m) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by HE4 Lentiviral Activation Plasmid (m) and HE4 Lentiviral Activation Plasmid (m2) target distinct regulatory regions of the Wfdc2 promoter. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HE4 Lentiviral Activation Particles (m) | sc-426693-LAC | 200 µl | $455.00 |
Wfdc2 encodes HE4, a secreted whey acidic protein (WAP) domain–containing protease inhibitor implicated in epithelial differentiation, extracellular protease regulation, and remodeling of the local tissue microenvironment. In mouse systems, HE4 expression is linked to epithelial barrier biology and inflammatory context–dependent programs that shape cell–cell adhesion and extracellular matrix dynamics. By modulating proteolysis and protease-activated signaling cues, HE4 can influence processes such as migration, invasion-like behavior in vitro, and stress-responsive transcriptional states. Altered WFDC2/HE4 regulation has been used as a molecular correlate in cancer- and inflammation-oriented research, supporting its relevance for mechanistic studies of epithelial pathophysiology.
HE4 Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Wfdc2 upregulation across a broader range of human cell types.
HE4 Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Wfdc2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous HE4 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Wfdc2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.